Shares of Lupin Ltd were trading in the green and 1% higher on 19 December after the company announced receiving approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Emtricitabine and Tenofovir Alafenamide Tablets. 

Emtricitabine and tenofovir alafenamide are used to treat HIV infection in combination with other drugs. HIV is the virus that causes acquired immunodeficiency syndrome (AIDS). This drug is also used for pre-exposure prophylaxis (PrEP), which reduces the risk of HIV-1 infection.

This drug is a generic equivalent of Descovy Tablets, which are manufactured by Gilead Sciences, Inc. Lupin was one of the initial ANDA candidates and is eligible for 180 days of shared generic exclusivity. This product will be manufactured at the Lupins facility in Nagpur, India.

Mumbai-based Innovation is what drives the global pharmaceutical company Lupin. In addition to the United States, India, and Australia, it develops and markets a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets throughout the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

At 11:32 am, the shares of Lupin were trading 0.77% higher at Rs 2,115.40 on NSE. 

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!